Filing Flows › AIM ImmunoTech (AIM) › Who owns the stock
Who owns AIM ImmunoTech (AIM) stock
18 funds reported AIM ImmunoTech (AIM) shares in their latest 13F filings, worth $345K in all. The largest holder is Jane Street Group, LLC ($229K). Last quarter 9 funds added to their stakes and 3 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Jane Street Group, LLC | 807,885 | $229K | increase | 2026-06-30 |
| Virtu Financial LLC | 124,269 | $35K | increase | 2026-06-30 |
| Vanguard Group | 17,502 | $20K | unchanged | 2025-12-31 |
| Morgan Stanley | 50,864 | $14K | increase | 2026-06-30 |
| Geode Capital Management, LLC | 46,003 | $13K | increase | 2026-06-30 |
| Goldman Sachs Group | 32,444 | $9K | new | 2026-06-30 |
| UBS Group AG | 28,931 | $8K | increase | 2026-06-30 |
| Susquehanna International Group, LLP | 21,859 | $6K | new | 2026-06-30 |
| Vanguard Fiduciary Trust | 17,519 | $5K | unchanged | 2026-06-30 |
| Ground Swell Capital, LLC | 12,222 | $3K | new | 2026-06-30 |
| Tower Research Capital LLC | 4,668 | $1K | unchanged | 2026-06-30 |
| Continuum Advisory, LLC | 500 | $142 | new | 2026-06-30 |
| Community Bank, N.A. | 132 | $36 | unchanged | 2026-06-30 |
| Osaic Holdings | 15 | $3 | unchanged | 2026-06-30 |
| Hoey Investments | 10 | $2 | unchanged | 2026-09-30 |
AIM ImmunoTech's latest quarter
AIM ImmunoTech, Q2 2026: revenue $26K (+4% year over year), net loss $3.8M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most AIM stock?
By the latest 13F filings: Jane Street Group, LLC ($229K); Virtu Financial LLC ($35K); Vanguard Group ($20K); Morgan Stanley ($14K); Geode Capital Management, LLC ($13K).
What is the short interest in AIM?
1,079,889 shares were sold short at the 2026-10-15 settlement, -23.26% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.